文献速递骨质疏松与代谢性骨病

Wnt信号与硬化蛋白在骨骼中的作用及其作为骨骼疾病治疗靶点的研究

Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
PubMed 文献 · Osteoporos Int · 2022-08-18

本文综述Wnt信号通路及骨组织特异性抑制因子硬化蛋白在骨代谢和骨骼疾病中的作用,并总结抗硬化蛋白抗体治疗低骨量疾病的研究现状。动物研究显示靶向硬化蛋白可恢复骨量、骨强度并预防脆性骨折,在骨质疏松、成骨不全和骨质疏松-假性胶质瘤中安全有效。目前仅人源化单克隆抗硬化蛋白抗体romosozumab获批用于骨质疏松临床治疗,可增加多个骨骼部位骨密度并减少男性和女性骨质疏松患者新发椎体、非椎体和髋部脆性骨折。

要点

  • Wnt信号通路是骨骼发育和骨稳态的关键调节者,其通路组分、抑制因子和增强因子的胚系突变可导致罕见先天性代谢性骨病。
  • 硬化蛋白由骨细胞分泌,是Wnt/β-catenin通路的骨组织特异性抑制因子,负向调节成骨分化和骨形成,并促进破骨细胞生成和骨吸收。
  • 动物模型研究显示靶向硬化蛋白可恢复骨量、骨强度并预防脆性骨折,在骨质疏松、成骨不全和骨质疏松-假性胶质瘤中安全有效;romosozumab是唯一获批用于骨质疏松临床治疗的人源化单克隆抗硬化蛋白抗体。

核心结论

  • 临床前研究证实抗硬化蛋白单克隆抗体治疗在骨质疏松以外的低骨量临床表型中可安全有效地保持/恢复骨量和预防脆性骨折,有待临床研究验证以获批转化进入主流临床实践。
  • 目前仅romosozumab(人源化单克隆抗硬化蛋白抗体)获批用于人类骨质疏松临床治疗,显示可增加多个骨骼部位骨密度并减少男性和女性骨质疏松患者新发椎体、非椎体和髋部脆性骨折。

研究设计与样本

  • 本文为综述,回顾当前关于硬化蛋白和Wnt通路在骨代谢和骨骼疾病中作用的知识,以及硬化蛋白中和抗体治疗低骨量疾病的最新进展。

主要发现

  • 多种针对人类低骨量疾病动物模型的体内研究显示,靶向硬化蛋白以恢复骨量、恢复骨强度和预防脆性骨折在骨质疏松、成骨不全和骨质疏松-假性胶质瘤中安全有效。
  • Romosozumab可增加多个骨骼部位骨密度,并减少男性和女性骨质疏松患者新发椎体、非椎体和髋部脆性骨折的发生。

临床怎么用

  • Romosozumab目前用于骨质疏松治疗。
  • 抗硬化蛋白单克隆抗体在骨质疏松以外低骨量临床表型中的治疗有待临床研究验证以获批转化进入主流临床实践。

局限性

  • 抗硬化蛋白单克隆抗体在骨质疏松以外低骨量临床表型中的治疗需经临床研究验证以获批转化进入主流临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Wnt signaling and its bone tissue-specific inhibitor sclerostin are key regulators of bone homeostasis. The therapeutic potential of anti-sclerostin antibodies (Scl-Abs), for bone mass recovery and fragility fracture prevention in low bone mass phenotypes, has been supported by animal studies. The Scl-Ab romosozumab is currently used for osteoporosis treatment. INTRODUCTION: Wnt signaling is a key regulator of skeletal development and homeostasis; germinal mutations affecting genes encoding components, inhibitors, and enhancers of the Wnt pathways were shown to be responsible for the development of rare congenital metabolic bone disorders. Sclerostin is a bone tissue-specific inhibitor of the Wnt/β-catenin pathway, secreted by osteocytes, negatively regulating osteogenic differentiation and bone formation, and promoting osteoclastogenesis and bone resorption. PURPOSE AND METHODS: Here, we reviewed current knowledge on the role of sclerostin and Wnt pathways in bone metabolism and skeletal disorders, and on the state of the art of therapy with sclerostin-neutralizing antibodies in low-bone-mass diseases. RESULTS: Various in vivo studies on animal models of human low-bone-mass diseases showed that targeting sclerostin to recover bone mass, restore bone strength, and prevent fragility fracture was safe and effective in osteoporosis, osteogenesis imperfecta, and osteoporosis pseudoglioma. Currently, only treatment with romosozumab, a humanized monoclonal anti-sclerostin antibody, has been approved in human clinical practice for the treatment of osteoporosis, showing a valuable capability to increase BMD at various skeletal sites and reduce the occurrence of new vertebral, non-vertebral, and hip fragility fractures in treated male and female osteoporotic patients. CONCLUSIONS: Preclinical studies demonstrated safety and efficacy of therapy with anti-sclerostin monoclonal antibodies in the preservation/restoration of bone mass and prevention of fragility fractures in low-bone-mass clinical phenotypes, other than osteoporosis, to be validated by clinical studies for their approved translation into prevalent clinical practice.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Marini F, Giusti F, Palmini G, et al. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders. Osteoporos Int. 2022. PMID: 35982318. doi:10.1007/s00198-022-06523-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。